Trials / Unknown
UnknownNCT04714060
UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals
A Randomized, Single-blind, Dose-selected Phase II Trial to Evaluate the Safety and Efficacy of UB-621 in Adults With Recurrent Genital HSV-2 Infection
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
A randomized, single-blind, dose-selected phase II trial to evaluate the safety, efficacy and PK of UB-621 in adults with recurrent genital HSV-2 infection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | UB-621 | mAb by SC administration |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2024-10-01
- Completion
- 2025-01-31
- First posted
- 2021-01-19
- Last updated
- 2022-05-18
Source: ClinicalTrials.gov record NCT04714060. Inclusion in this directory is not an endorsement.